Royal Bank of Canada
AUPH icon

Royal Bank of Canada’s Aurinia Pharmaceuticals AUPH Stock Holding History

Royal Bank of Canada’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-221,000
Closed -$2.86M – 7615
2021
Q2 		$2.86M Buy
+221,000
New +$2.82M ﹤0.01% 2749

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Bank of Canada's AUPH Position: Q1 2026 in Review

Royal Bank of Canada reduced its Aurinia Pharmaceuticals (AUPH) stake by 27% in Q1 2026, selling an estimated $60.2K and leaving 10,977 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.

Royal Bank of Canada first reported a position in AUPH in Q3 2014 and has held it in 47 quarters since. The position peaked at $3.25M in Q1 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Royal Bank of Canada held 10,977 shares of Aurinia Pharmaceuticals worth $163K as of Q1 2026.
  • Royal Bank of Canada sold 4,116 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $60.2K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4831 holding.
  • Royal Bank of Canada first reported a position in Aurinia Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
  • Royal Bank of Canada's Aurinia Pharmaceuticals position peaked at $3.25M in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.